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Abstract
Background: Economic evaluation has been implemented to inform policy in many areas, including coverage
decisions, technology pricing, and the development of clinical practice guidelines. However, there are barriers to
evidence-based policy in low- and middle-income countries (LMICs) that include limited stakeholder awareness,
resources and data availability, as well as the lack of capacity to conduct country-specific economic evaluations.
This study aims to survey health policy experts’ opinions on barriers to use of cost-effectiveness data in these
settings and to obtain their advice on how to make a new cost-per-DALY database being developed by Tufts
Medical Center more relevant to LMICs. It also identifies the factors influencing transferability.
Methods: In-depth interviews were conducted with 32 participants, including policymakers, technical advisors, and
researchers in Health Ministries, universities and non-governmental organisations in Bangladesh, India (New Delhi,
Tamil Nadu and Karnataka) and Vietnam.
Results: The survey revealed that, in all settings, the use of cost-effectiveness information in policy development is
lacking, owing to limited knowledge among policymakers and inadequate human resources with health economics
expertise in the government sector. Furthermore, researchers in universities do not have close connections with health
authorities. In India and Vietnam, the demand for evidence to inform coverage decisions tends to increase as the
countries are moving towards universal health coverage. The informants in all countries argue that cost-effectiveness
data are useful for decision-makers; however, most of them do not perform data searches by themselves but rely on
the information provided by the technical advisor counterparts. Most interviewees were familiar with using evidence
from other countries and were also aware of the influences of contextual elements as a limitation of transferability.
Finally, strategies to promote the newly developed database include training on basic economic evaluation for
policymakers and researchers, and effective communication programs, with support from reputable global agencies.
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Conclusions: Although cost-effectiveness information is recognised as essential in resource allocation, there are several
impediments in the generation and use of such evidence to inform priority setting in LMICs. As such, the Cost-per-
DALY database should be well-designed and introduced with appropriate promotion strategies so that it will be
helpful in real-world policymaking.
Keywords: Cost per DALY, Economic evaluation, Registry, Database, Policy decisions, Low- and middle-income
countries
Background
Countries increasingly recognise the need to allocate lim-
ited healthcare resources efficiently [1]. To this end, eco-
nomic evaluation has been implemented in many areas,
including coverage decisions, technology pricing and the
development of clinical practice guidelines [2, 3]. Al-
though economic evaluation is much more prevalent in
high-income countries (HICs) [4], it may in principle
make a bigger impact in low- and middle-income coun-
tries (LMICs) given the pressing needs in those settings
[5, 6]. However, there are barriers to evidence-based
policy in these countries that include limited stakeholder
awareness, resources and data availability [7, 8], as well as
the lack of capacity to conduct country-specific economic
evaluations [9]. Given the wide practice of using economic
evidence to inform resource allocation in HICs, there are
a number of studies that address these issues in these
settings [10–12]. On the contrary, literature in LMICs is
lacking despite the significant need.
The development of a database that systematically cata-
logues the literature would benefit decision-makers in
LMICs, which lack capacity in health economics [13, 14].
Existing examples include the database at the University
of York’s Centre for Reviews and Dissemination and Tufts
Medical Center’s Center for the Evaluation of Value and
Risk in Health (CEVR) Cost-Effectiveness Analysis (CEA)
Registry (www.cearegistry.org). Most of the studies in-
cluded in these databases are from HICs because the
numbers of economic evaluations, especially cost-per-
Quality Adjusted Life Year (QALY) analysis, in HICs are
much higher than the LMICs counterpart. The strength of
the University of York database is its inclusion of
studies using either of two health metrics (QALY and
Disability Adjusted Life Year (DALY)), and its provision
of quality appraisals for each study. However, this
database does not synthesise results from multiple
studies in a single table, and its query function is
limited (for example, it is not possible to search based
on target population age or study perspective) [15].
Furthermore, the York Centre for Reviews and Dissem-
ination database has discontinued updates. On the
other hand, the Tufts CEA Registry synthesises results,
but includes only cost-per-QALY studies and is not
completely publicly accessible [16].
The relative merits of the cost-per-DALY averted and
cost-per-QALY measures have been debated extensively
[17–19]. Although the literature contains far more cost-
per-QALY articles than cost-per-DALY articles, the latter
metric is more common in studies of LMICs because
the international development organisations that fund
this work, such as the WHO and the Bill & Melinda
Gates Foundation (BMGF), favour use of DALYs [20].
The WHO Cost-Effectiveness and Strategic Planning
(WHO-CHOICE) program has a compilation of cost-
per-DALY studies, but its contents are limited to WHO-
sponsored studies [21].
Recognising the importance of a cost-per-DALY data-
base for LMICs, the BMGF has funded Tufts Medical
Center’s CEVR to develop a cost-per-DALY Registry.
The Registry aims to inform decision-makers on how to
best improve health resource allocation and to enhance
the use of standard methodologies by technical advisers.
However, because economic evaluations are not neces-
sarily generalisable1 or easily transferable to local set-
tings,2 development of a database per se does not ensure
its use. This is the first qualitative study to determine
the barriers that influence use of cost-effectiveness data
in LMICs and obtain advice from relevant stakeholders
on how to make the new cost-per-DALY database being
developed by CEVR more relevant to these settings. It
also explores the usefulness of a cost-per DALY database
to health policymakers and other stakeholders, and iden-
tifies the factors influencing transferability. Given that
cost-per-DALY analysis has been primarily conducted in
LMICs, the majority of studies included in the new
Registry will be from resource-poor settings, dissimilar
to cost-per-QALY databases that focus on HIC studies.
Methods
Samples: settings
The study settings were purposively chosen. The selected
countries – Bangladesh, India and Vietnam – though
limited to Asia, represent a range of health expenditures
per capita and coverage of public health insurance [22].
Because India’s health systems are run by its constituent
states, three states were selected to represent central and
state health systems (including one richer and one poorer
state) and to represent a range of development. Interviews
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were conducted in Dhaka, Bangladesh; New Delhi (where
the federal government is located); Bangalore and Karna-
taka (low income and less developed health systems);
Chennai, Tamil Nadu (higher income and more developed
health systems); and Hanoi, Vietnam. Other factors
considered in the selection of study settings were a
lack of established health technology assessment
(HTA) systems, limited economic evaluation capacity
and the feasibility of traveling from Thailand to con-
duct face-to-face interviews.
Table 1 describes the study settings. The health ex-
penditure per capita in Bangladesh, India and Vietnam is
US$67.8, US$157 and US$234, respectively [23]. Mean-
while, the coverage of government health schemes varies
from 1% in Bangladesh to 20% in India and 60% in
Vietnam. The proportion of healthcare that is paid for
out-of-pocket is relatively high in these three countries.
Document review
Reviews of relevant documents were conducted during
December 2013 to February 2014 as a means to gather
information on the health systems context and existing
capacity for economic evaluation in the study settings.
The reviews involved reports issued by country/state
governments and international agencies, as well as
published articles in peer-reviewed journals. Together
with interview information, these documents help
enhance understanding on the roles of health author-
ities, current direction of and progress in health sector
reforms, need for evidence to guide resource allocation,
and limitations in health economic capacity.
In-depth interviews
Semi-structured, in-depth interviews with key stake-
holders were employed as the major approach for data
collection in this study.
Samples: interviewees
The interviewees were initially identified from networks
of the Health Intervention and Technology Assessment
Program (HITAP), namely the CAPacity building pro-
gram on Universal Health Coverage and the Mahidol
University Global Health program in Thailand, and the
National Institute for Health and Care Excellence’s Inter-
national Unit, United Kingdom. The search targeted
decision-makers responsible for health resource alloca-
tion at the national- or state-level; technical officers,
including researchers and those who advise health pol-
icymakers; or policy analysts in non-profit organisations
with good knowledge of the local context.
Invitations to participate were sent via emails to
describe the study’s purpose and the interview protocol.
A snowball technique was also employed to identify rele-
vant interviewees (about 2–3 persons). Fifty-one partici-
pants were invited, including 12 from Bangladesh, 28
from the three Indian states, and 11 from Vietnam. The
response rate was 63% (32 participants), including 10
from Bangladesh, 15 from India, and 7 from Vietnam.
Profiles of the interviewees are shown in Table 2.
Interviews
During January to March 2014 four HITAP staff mem-
bers conducted the interviews, using interview materials.
Samples of the results by search options are shown in
the supporting information section. Basic search is used
for quick search for articles, ratios and utility weights.
Briefly, results by articles show detailed information (i.e.
publication year, journal and article title) of retrieved
papers matched with the search term. Results by ratio
show cost-per-DALY information of each paired inter-
vention and its comparator in a given setting of selected
studies. Results by weight show disability weight of each
health condition in selected studies. Since the back-
ground of interviewees are very varied and some
might not have used economic evaluation results
before, the researchers provided brief information of
the concept of DALYs and a real case study of an
economic evaluation conducted in Thailand in order
to facilitate the discussion.
Advanced search can be used to search for more
complex queries and specific issues. Users can choose to
select country of interest, publication date, study themes,
intervention type, prevention stage, disease, time hori-
zon, perspective, or quality of study. Moreover, they can
search by specific ratio, impact type and budget impact,
and utility weights information.
Table 1 Background information of Vietnam, India and Bangladesh
Country/States Bangladesh India Tamil Nadu Karnataka Delhi Vietnam
Populationa (million) 155 1240 72 64 9 91
GDP per capitab (Current US$, 2012) 750 1503 1844 1441 3762 1755
Health expenditure per capitaa (% of GDP) 67.8 (6.6%) 157 (4.1%) N/A N/A N/A 234 (6%)
Out-of-pocket as a percentage of total expenditure on healtha 63% 58% N/A N/A N/A 49%
Percentage of people covered by public health insurance 1% (24) 20% (25) 18% (26) N/A N/A 60% (27)
Year by which they plan to achieve Universal Health Coverage 2032 2022 2020
Sources: aWHO [23]; bWorld Bank [28], Planning Commission, Government of India [29]
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IY and NT were involved in all settings, and YT and
ST alternated between study settings. This scheme en-
sured the interviews were administered consistently
across all settings. Semi-structured interviews were
conducted in English with decision-makers and technical
officers to gather their views on: (1) the current situation
of health decision-making and the role of economic
evaluation as well as other types of evidence; (2) the use-
fulness of cost-per-DALY information; (3) desirable
characteristics of a cost-per DALY database; and (4)
factors influencing the transferability of cost-per-DALY
information across countries. The interview guide ques-
tions are listed in the supporting information section.
An interpreter was provided in the case of some of the
respondents from Vietnam. Each interview lasted 40 to
50 minutes. Interview sessions were tape-recorded
unless otherwise requested. In some cases and as re-
quested, the interview materials were sent to the inter-
viewees after the interview for further comments and
suggestions.
Data analysis
Interviews were transcribed non-verbatim for qualitative
thematic analysis. Key elements (themes and subthemes)
were identified from transcripts, as informed by the
study objectives, related interview questions and other
factors. These factors included the interviewee’s under-
standing of economic evaluation and the cost-per-DALY
metric; processes and information requirements for
health policy decisions; economic evaluation capacity of
the country (including capacity in the Ministry of Health
(MoH), universities and research institutes); the inter-
viewee’s perception of the usefulness of cost-per-DALY
information; his/her opinion about desirable database
characteristics and the transferability of cost-effectiveness
evidence; and interviewee suggestions to enhance the
database and general comments. Thematic statements
were arranged under relevant headings. IY, NT and ST in-
dependently reviewed and interpreted the retrieved infor-
mation. A meeting was organised for the three researchers
to exchange their findings. For the issues that generated
different opinions, corresponding interview transcripts
were revisited and the discussion was carried on until con-
sensus was reached.
Results
Economic evaluation in Bangladesh
In 2012, Bangladesh adopted a universal health coverage
(UHC) program guided by a health financing study;
however, current insurance coverage is less than 1% of
its total population [24]. The Ministry of Health and
Family Welfare (MoHFW) plays a pivotal role in health
policies formulation. External sources of finance account
for 7.2% of total health expenditure [25], with major
donors including the World Bank and the Asian Devel-
opment Bank [26]. Resources are allocated through the
Health Population Nutrition Sector Development
Program 2011–2016. The 32 operational plans of this
program highlight the competing demands for limited
resources. In addition, BRAC (an NGO), substantially
contributes to the funding, development and implemen-
tation of public health programs in this country.
Economic evaluation expertise in Bangladesh is lim-
ited, although there are two health economics units in
the MoHFW, University of Dhaka and International
Center for Diarrheal Disease Research, Bangladesh
(icddr,b) – a non-governmental research institute. The
interviewees explained that the number of health econo-
mists is inadequate. While both the demand for health
economists in the MoHFW and the number of trained
students has been growing, government officer positions
have not likewise increased. As a result, graduates from
the University do not work in health economics. In
addition, local data are not available and the budget for
data collection is insufficient. This results in the limited
number of economic evaluation studies available locally.
Most health economics studies focus on costs only. The
icddr,b conducts cost-effectiveness analysis of some
public health interventions developed by its researchers,
and also offers short-course trainings on health econom-
ics to health personnel. Nevertheless, such an effort to
build capacity in this area yields limited impact in both
academic and policymaking spheres.
Economic evaluation in India
In India, the federal government is responsible for
national strategic planning (e.g. the National Rural
Health Mission and Urban Health Initiative), for health
regulation (e.g. professional practice, health product
regulation, etc.), international health, and subsidisation
Table 2 Profiles of the interviewees




Number of policymakers at
Ministries of Health including




Number of technical advisors
within Ministries of Health and
academic units related to health
economics, health policy, and
health financing
4 10 4




Total 7 15 10
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for poor states. The federal government planned to
achieve UHC by 2022, which will require a substantial
increase in health expenditure [27], while the current
health spending is one of the lowest in the region and
indicates that resources might prove a constraint in scal-
ing up, necessitating better tools for prioritisation. How-
ever, the capacity of the MoH and Ministry of Finance
(MoF) on the costing of public health policies is limited
and should be strengthened before introducing eco-
nomic evaluation.
According to the Indian Constitution, each state has
its own healthcare system and is responsible for the
health of its respective population. The selected states
provide public health insurance for poor families up to a
certain level. For example, in Karnataka, the Vajpayee
Arogyashree scheme, introduced in 2010 for those below
the poverty line, focuses only on tertiary healthcare in
seven specialties (cardiovascular, oncology, renal dis-
eases, neurosurgery, neonatal surgeries, burns, and poly-
trauma) [28]. There are other similar state governments’
schemes running in a number of states.
Interviewees said that the use of economic evaluation
to inform policy in India is currently in its initial stages
and there is not enough understanding of it. The dual
source of policymaking – at the Centre and at the states
– makes the situation more complex. Similar to the fed-
eral government, economic evaluation is not used by the
state governments because decision-makers currently do
not demand it or lack the capacity to supply economic
evidence. Moreover, there is no official mechanism to in-
clude cost-effectiveness evidence in the decision-making
process. Nevertheless, the research capacity of economic
evaluations is available in academic institutes, some of
which are well recognised at the global level.
Economic evaluation in Vietnam
Health resource allocation in Vietnam is mainly under-
taken by multi-departmental committees, chaired by the
Health Minister. Requirements for formulation of the
medicine reimbursement list include clinical efficacy,
market approval, prescriber experience and prices. Ac-
cording to interviewees, due to severe fiscal constraints
in recent years, decision-makers now pay significant
attention to budget implications and value for money
when evaluating new technologies and interventions.
During the last 5 years, the MoH implemented a policy
to build the country’s HTA capacity to achieve sustainable
UHC by 2020 [27]. This initiative will increase the
demand for cost-effectiveness evidence. On the supply side,
the Health Strategy and Policy Institute, which resides
within the MoH, is responsible for generating evidence.
There is an increasing interest to incorporate eco-
nomic evaluation in coverage decisions under the UHC
program managed by the Vietnamese Social Security.
The Health Strategy and Policy Institute has been tasked
to review the existing pharmaceutical and health services
packages with the aim to introduce the new Basic Health
Service Package by 2018. A systematic review of eco-
nomic evaluation conducted in Vietnam reveals that, in
order to meet the government policy demand, there is
an urgent need to improve technical capacity of local re-
search scholars/institutes, and in some instances, the
transfer of health economic evidence from countries in
the same region will be helpful for policymaking [28].
Usefulness of cost-per-DALY information
A greater role for economic evaluation in these settings
can be anticipated given the pledge by Vietnam and
India to introduce UHC. There is increasing pressure
to adopt new and high-cost technologies, and most of
the interviewees in these settings agree that cost-per-
DALY information is critical. However, they also noted
that policymakers rarely search for this kind of infor-
mation. Their decisions are instead based on data ana-
lysis results and other information provided by the
technical advisor counterparts who serve as the com-
mittees’ secretariat.
The interviews revealed that the cost-per-DALY concept
is not well understood among most policymakers and
technical officers. It is also not well-understood among
many researchers and physicians who sit on the decision-
making committees. This was evident in Vietnam, even
though this country has used ad hoc cost-effectiveness in-
formation to formulate health-related policies such as
coverage for some expensive medicines. The gap in
knowledge can be attributed to the lack of institutiona-
lisation of health economics in the MoH. Instead, in
the countries studied, the focus is on cost and budget
implications. Many interviewees recognised that this
focus biases policy towards low-cost interventions while
sometimes rejecting interventions with better outcomes
but higher costs. For this reason, these interviewees
stated that a well-designed cost-per-DALY database
would be very useful.
Desirable characteristics of a cost-effectiveness database
Most interviewees argued that the Tufts CEA Registry,
as described by the researchers and illustrated in the
interview materials, was not user-friendly. A major
complaint was that the existing Registry does not allow
users full access to the database via advanced search
(available in ‘premium access’) if they are not a paid
member. In addition, the database does not allow users
to download or extract results to other formats such as
excel file. They added that the database should be freely
accessible, be available online, require no special soft-
ware to use, and should include an online user manual.
Further suggestions are provided below.
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Search options
Two of the interviewees recommended use of World
Bank geographic classifications (e.g. Asia, Africa and
Latin America) and economic development levels (i.e.
low, lower-middle, upper-middle and high income).
Furthermore, they recommended having provincial-
level information for larger countries such as India and
China. It was also suggested that the search options are
standardised globally and searchable using the Inter-
national Classification of Diseases system. For demo-
graphic groups, many interviewees suggested use of
broadly recognised categories, e.g. children under 5
years old, teenagers and women of reproductive age,
because these terms are in line with the design of pub-
lic health programs. Most interviewees in Bangladesh
and India suggested the inclusion of vulnerable groups
or poor people since they are of high concern to the
governments in these countries.
Finally, it was recommended that the database be
searchable using multiple keywords combined using
Boolean operators (AND, OR, NOT). If appropriate,
drop down options or autocomplete function should
be used. Definitions should be provided for terms not
familiar to persons outside particular disciplines. For
example, the term ‘time horizon’ may not be well
understood by users who are not health economists.
Contents
The cost-per-DALY database should contain reliable,
updated and comprehensive data. Technical officers
recommended inclusion of reputable “grey” literature
such as reports produced by reliable sources like the
WHO, BMGF and national governments. All economic
evaluation studies in this database should be graded for
their technical robustness using international classifica-
tion standards. In addition, the database should be able
to characterise changes in cost-effectiveness informa-
tion for particular interventions over time and across
countries or regions. The interviewees recommended
inclusion of both cost-per-DALY and cost-per-QALY
estimates in a single consolidated database for LMICs.
Furthermore, most technical officers and researchers
interviewed in this study recommended reporting the
perspective used by each study, the study sample size
and budget impact estimates, if available. Ex-ante
model-based economic evaluation (on unimplemented
policies) versus ex-post economic evaluation (using
data from real policy implementation) were also
identified to be coded differently. The interviewees
explained that they are likely to value ex-post evalua-
tions more than ex-ante ones since the former is
perceived to be proven as opposed to something
assumed.
Results presentation
In the interviews, health economists and technical offi-
cers cited the CEA Registry’s synthesis of results from
multiple studies in a single table as helpful. They also
suggested that the search results be presented in various
formats, such as graphs, diagrams or figures so that they
are easy to understand. A few interviewees referred to
the Institute of Health Metrics and Evaluation’s data
visualisation [29]. Some interviewees requested the
display of additional information, including the study
setting context, e.g. whether UHC has been imple-
mented, how much of the country’s output is spent on
health, who pays for interventions and disease burden.
The interviewees recommended use of standard terms,
including nominal and international dollars3 and provide
information for calculation purposes. The database
should report on potential conflicts of interests, i.e.
funding. Subjective quality scores4 should be accompan-
ied by a description of the methods used. Ethical issues
and disclaimers should also be clarified. The inter-
viewees stated incorporation of search screens and out-
put formats similar to those used by the WHO or the
World Bank would facilitate use of the cost-per-DALY
database.
Transferability
Most interviewees were familiar with the influence of
contextual factors on the use of overseas data in their
country. Although the most senior decision-makers in
Vietnam, such as the Health Minister and Vice Minis-
ters, requested technical staff to include a chapter on
international literature reviews in policy proposal
documents, information from countries such as Europe
and North America are only used as reference or
background information. Conversely, information from
surrounding geographic areas with similar cultures or
health systems (such as Thailand in the case of India
and Vietnam or India and Nepal in the case of
Bangladesh), are most influential.
Ten health economist interviewees pointed out that
given the differences in the health systems, researchers
should not rely on economic evaluations conducted in
other countries. The main barriers to using cost-
effectiveness information across countries are differ-
ences in costs and clinical practice. No interviewee
accepted the generalisability of cost-effectiveness
information across settings, but they did agree that eco-
nomic evaluation studies can be used in different set-
tings if locally relevant information is used to develop
model assumptions. As a result, studies in the database
can be useful for providing background information,
analytical frameworks, retrieving clinical efficacy or
effectiveness data, and comparing results.
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Interestingly, the interviewees implied that the inter-
pretation of the information provided by the database
should not be based on the conclusion of the majority of
studies, but rather on the conclusions of studies that are
most contextually relevant. For example, if most studies
for a particular intervention indicate it is cost-effective
but the study settings are not representative of the user’s
setting, the results will be less meaningful than results
from a more limited number of studies that are repre-
sentative of similar settings.
Promoting the database in LMICs
Economic evaluation should be promoted among key
figures in the MoH and MoF. Other targeted users
should include policymaking committees, leading health
professionals and academicians, and non-health sector
decision-makers.
As suggested by the respondents, a database should be
introduced along with efforts to improve knowledge
about cost-effectiveness analysis and the capacity to con-
duct it. The joint introduction of the database and the
education efforts will help ensure that the database is
not used inappropriately. It will also give users an oppor-
tunity to learn how to present the data extracted from
the database so that it is relevant to decision-makers.
Training workshops should be held to provide hands-on
experience and promote an understanding of the cost-per-
DALY metric. The database can be integrated as part of
the strategy of moving towards UHC. Workshops can be
held through a regional or global initiative such as the
WHO regional workshops on UHC or Joint Learning
Network on UHC (www.jointlearningnetwork.org).
Additionally, a communication strategy should be
planned. The CEVR team should collaborate with reput-
able organisations such as the WHO or World Bank to
help promote the database to its Member states and
partners. The CEVR might also consider coordinating with
HTA networks such as the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR),
Health Technology Assessment international (HTAi), and
the International Decision Support Initiative (iDSI). Social
networks can be an effective channel to inform individuals.
Monitoring and evaluation
The database should be monitored and evaluated,
especially during the first 1–2 years following its intro-
duction, with feedback used to guide further develop-
ment. The interviewees in Bangladesh suggested that the
database website include a feature to allow users to
communicate with the developers, e.g. via blogs, com-
ment boxes or electronic feedback forms. This feature
can serve many purposes, including identification of
studies that should be included in the database or notifi-
cation of incorrect database information.
Some interviewees also mentioned that external assessment
could be conducted by a third party on an ad-hoc basis to
create trust among users regarding the database’s quality and
reliability. Building this kind of trust is crucial to promoting
the database’s legitimacy among potential government users.
Discussion
Respondents in this study confirmed that the cost-per-
DALY registry would be useful for LMICs, which typically
have limited economic evaluation capacity. Characteristics
that would encourage database use include:
1. Rather than cost-effectiveness league tables that rank
health investment independent of disease areas and
target population groups, decision-makers often
want information to evaluate investments to address
particular problems for particular groups, e.g.
whether and how to control tuberculosis among
migrant workers. Search functionality should ensure
that the database can address a wide range of
specific policy questions.
2. Although this study focused on the cost-per-DALY
metric, the database should also include cost-per-
QALY information from the same search engine.
This is because the users want to make the best use
of all available information rather than selective
information when making policy decisions.
3. If the registry targets national governments, it must
establish credibility by gaining endorsements by
reputable global health authorities. Interviewees
suggested strategic collaborations with major global
health partners and rigorous internal and external
monitoring. External monitoring should be
conducted by an independent body, preferably a
consortium of partners, including experts from
international governmental organisations, HTA
agencies from LMICs, and academics from target
countries. Meanwhile, partners should be identified
to promote the database in their individual countries
and to identify unpublished studies from their
countries for inclusion in the database.
4. The database should improve local capacity for
health economics by including basic information
on research methods, and by promoting the
conduct of future studies for specific settings.
For example, the database website describes the
limitations of published studies and how the same
intervention can produce different results in
different settings. The BMGF should not only
fund database promotion but also support training
sessions, activities or workshops for countries that
are ready to conduct local economic evaluations.
Technical officers from the MoH and MoF are
among the top priorities.
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Given that, when time passes, the price of a technol-
ogy usually decreases and prescribers acquire experience
about the use of particular technologies that result in
better health outcomes, the cost-effectiveness results will
change in a desirable way. Such an occurrence should
be revealed by the database when it includes cost-
effectiveness studies of the same health technology that
are conducted at different times.
This study has limitations. First, the limited number of
interviewees might have an effect on the breadth of the
information acquired. However, as we observed during
the data collection, there was general agreement among
different interviewees on the key issues, suggesting that
the weight of this limitation on the key findings may not
be significant. Second, although this research focused on
informing decision-making at the national level, other
groups could also be relevant, such as international
donors, who fund vertical programs in LMICs; intergov-
ernmental organisations, who offer policy recommenda-
tions to country governments; academics, who may use
the database for teaching purposes; and industry, which
can use the information for research and development
planning or marketing purposes. Third, because our in-
terviews were limited to three countries, generalisations
should be made with caution.5 Furthermore, the inter-
viewees were identified through international networks
of HITAP, which may pose biases, such as obtaining
results that are favourable to economic evaluation evi-
dence. Fourth, some of the interviewees had limited
knowledge of or experience with economic evaluation.
As a result, some may have misinterpreted or misunder-
stood the issues that the survey explored. Nevertheless,
if the interviewers recognised such a problem, they tried
to provide explanation and clarification. Finally, the
interview materials were taken from the existing Tufts
CEA Registry, and not from the cost-per-DALY Registry
because the latter was still under development during
the data collection phase of this study. In addition, the
interview materials were paper-based, making it imprac-
tical for interviewees to truly test the website.
The findings from this study should prove helpful for
the further development and refinement of the Tufts
cost-per-DALY database, which is now available, and for
future outreach efforts to engage with decision-makers
about resource prioritisation using cost-per-DALY stud-
ies. In particular, based on feedback received in this
study, as well as other outreach efforts, the team at Tufts
Medical Center, which developed the cost-per-DALY
database, is considering a series of initiatives, including
constructing a list of interventions that represent ‘good
value’ in different regions and countries; developing edu-
cation and training opportunities based on the data;
improving the estimation of costs, so that they reflect
the needs of local decision-makers, and examining the
generalisability of studies conducted in one context to
another.
Conclusions
Although cost-effectiveness information is recognised as
essential in resource allocation, especially in resource-
finite settings, there are several impediments in the gen-
eration and use of such evidence to inform policy in
LMICs. As such, the well-designed cost-per-DALY data-
base is considered helpful among technical advisors and
health economic researchers. At the same time, respect-
ive institutes at national and international level should
introduce contextually-appropriate strategies to promote
the use of this registry in real-world policymaking.
Endnotes
1Generalisability is the degree to which the results of a
study or systematic review can be extrapolated to other
circumstances, in particular to routine healthcare
situations.
2Transferability is the ability to apply information and/
or data from one setting to the user’s target setting and
is dependent on context specificity.
3A nominal value is an economic value expressed in
historical nominal monetary terms while an inter-
national dollar is a value that has been adjusted and
measured in terms of the Purchasing Power Parity.
4A subjective rating score by reviewers from 1 (low-
est quality) to 7 (highest quality). Scores reflect the
following considerations (in order of importance): (1)
whether or not the authors correctly computed the
incremental cost-effectiveness ratios; (2) whether or
not the authors comprehensively characterised the
uncertainty of the results (see sensitivity analysis); (3)
whether or not the authors correctly used and expli-
citly specified the health economic assumptions used
in the study (e.g. discount rate, currency, time hori-
zon); and (4) whether or not the authors appropri-
ately and explicitly estimated the utility weights.
5As part of the same project, we also conducted a
parallel study using an electronic survey focusing on the
usefulness and transferability of economic evaluation,
which covers a range of countries in the Asian, African,
and South American regions.
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